Pharmaceutical

Coherus offloads Humira biosimilar Yusimry for $40m

Hong Kong King-Friend Industrial has acquired worldwide rights to Yusimry, and i...

Alumis raises $250m in IPO as biotech stock stirs

Though downsized, Alumis still clocked one of the largest IPOs within the biotec...

Holoclara gains Series A financing for worm-derived the...

Holoclara has secured $16m in a Series A financing to advance new worm-derived t...

Eisai and Biogen launch LEQEMBI for Alzheimer’s in China

Eisai and Biogen have announced the introduction of LEQEMBI (lecanemab) for the ...

US Justice Dept cracks down on healthcare fraud schemes...

Nearly 200 people have been charged with participating in healthcare fraud schem...

Supreme Court votes against Purdue Pharma’s opioid sett...

The US Supreme Court blocked $6bn opioid crisis settlement that would have shiel...

Novo Nordisk’s ocedurenone Phase III flop costs company...

NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from K...

FDA issues complete response to Daiichi Sankyo-MSD’s BL...

The US FDA has provided a complete response letter for Daiichi Sankyo and MSD’s ...

AbbVie gains FDA approval for EPKINLY in follicular lym...

AbbVie has announced the receipt of accelerated approval from the US FDA for EPK...

AI and stable funding environments are catalysts for bi...

As the funding market evolves, there is greater emphasis on companies having com...

2seventy bio completes $40m haemophilia A program deal ...

US-based 2seventy bio has completed an asset purchase agreement (APA) to divest ...

Verona scores FDA approval for Ohtuvayre as COPD mainte...

Ohtuvayre is expected to rake in $1.1bn in global sales from the market for COPD...

Biotech fund Curie.Bio augments reserves with $380m to ...

The recent raise will bring the biotech accelerator Curie.Bio’s total funds rais...